Fibrin Degradation Products

10-Q: RADIENT PHARMACEUTICALS CORP

10-Q: RADIENT PHARMACEUTICALS CORP

(EDGAR Online via COMTEX) -- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION & RESULTS OF OPERATIONS

This report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Quarterly Report to conform such statements to actual results or to changes in our expectations.

The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information appearing elsewhere in this Quarterly Report. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation the disclosures made under the caption "Management's Discussion and Analysis of Financial Condition and Results of Operations," and the audited condensed consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2010, previously filed with the U.S. Securities and Exchange Commission (SEC).

In 2011, Coagulation Testing Market: USA, Europe, Japan ...

/ PRNewswire / – Reportlinker.com announces that a new market research report is available in its catalog:

2011 Coagulation Testing Market: USA, Europe, Japan – Developing business opportunities and market development strategy, supplier

rising costs, reduce the pressure on industrial countries, along with continuing technological developments chromagenic substrates, monoclonal antibodies, immunology, molecular diagnostics and laboratory automation computers radically alter the coagulation testing practice during the next ten years. New specific and sensitive indicators of hemostasis increasingly used in automated equipment. Coagulation testing has also become more standardized, providing opportunities for quality control of products and services. In addition to the continuing decline in the hospital system and technology to facilitate the decentralization of the coagulation testing closer to the patient, which creates additional opportunities and challenges for suppliers.

content

Introduction

in the global market and technology overview

A.

LAND DEGRADATION, CREATION AND DESTRUCTION

Customer-centered products, creating successful products through smart requirements management

Medicinal Natural Products, A Biosynthetic Approach

Demystifying exotic products, interest rates, equities and foreign exchange

Non-timber forest products, medicinal herbs, fungi, edible fruits and nuts, and other natural products from the forest